UCB (OTCMKTS:UCBJF) Shares Gap Up – Still a Buy?

UCB SA (OTCMKTS:UCBJF)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $250.88, but opened at $258.4650. UCB shares last traded at $252.16, with a volume of 84 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Jefferies Financial Group raised UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler reiterated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, UCB presently has an average rating of “Moderate Buy”.

UCB Stock Up 1.5%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The company has a 50 day simple moving average of $276.22 and a two-hundred day simple moving average of $291.65.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.